Biotech
SJD and the Amancio Ortega Foundation Will Create a Research Center for Rare Diseases
The Amancio Ortega Foundation is investing 59 million euros to build the Únicas SJD precision medicine research center for rare diseases, part of the Porta Diagonal project. Set to open in 2026, the 14,000-square-meter, six-floor center will focus on genomic studies, cell and gene therapies, and neuromodulation, becoming one of the world’s largest, rare disease complexes.
Sant Joan de Déu (SJD) will have a new rare disease research center. The Amancio Ortega Foundation, linked to the owner of the fashion giant Inditex, will invest 59 million euros in building a center with which to carry out genomic studies and develop cell and gene therapies, deep stimulation or neuromodulation.
The research center will be called Únicas SJD precision medicine and will have 14,000 square meters distributed over six floors.
The opening of the new research center for rare diseases is scheduled for 2026
Work on the new research center started at the end of February with the laying of the first stone. In a statement, SJD noted that the building will become one of the three largest complexes in the world dedicated to rare diseases when it comes into operation.
Already then SJD announced that the building financed by the Amancio Ortega Foundation will be one of the nodes of the Únicas network , a network made up of thirty hospital centers throughout Spain promoted by the Sant Joan de Déu Hospital and the Spanish Federation of Rare Diseases (Feder ).
The research center will be part of the Porta Diagonal project, which also plans to house a biomedical campus
The new building is part of the new structures of the Porta Diagonal urban project, previously called Porta Barcelona, which foresees the creation of a biomedical campus in the area to accelerate the implementation of emerging technologies in the field of health.
At the end of January, the green light was given to move the Hospital Clínic in the Catalan capital to the sports area of the University of Barcelona (UB) campus on Diagonal. The transfer agreement was signed with a broad institutional agreement to build a 290,000 square meter health campus. The promoters of the initiative assure that the new center will host the healthcare activity that was already carried out on Villarroel Street in one of the “most advanced campuses in Europe.”
In this agreement for the construction of the Clínic Campus, the name of the initiative, its execution deadlines are not yet specified: it is just a commitment to urban reorganization between the municipalities involved in the project, Barcelona, l’Hospitalet and Esplugues del Llobregat.
__
(Featured image by Bermix Studio via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us
-
Markets2 weeks ago
Fed’s Bold 50 bp Cut: Do They Know Something We Don’t?
-
Impact Investing5 days ago
How Many European Companies Integrate SDGs Into Their Strategies
-
Cannabis2 weeks ago
Debunking Myths: The Truth About Medical Cannabis and Its Impact on Brain Health
-
Biotech3 days ago
Oryzon up 3% After Progress in Trial of Its Drug for Personality Disorder